Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Sold by DCF Advisers LLC

Key Points

• DCF Advisers LLC reduced its stake in Lifecore Biomedical by 10.6%, selling 56,989 shares in the first quarter, leaving them with 483,000 shares valued at $3.4 million.
• Insider trading activity saw major shareholder Aron R. English sell 1,139,504 shares for approximately $7.41 million, a significant 73.32% decrease in their position.
• Lifecore Biomedical's stock opened at $6.99, showing minor fluctuations with a 52-week range of $3.68 to $8.85, and a current market cap of $258.84 million.

DCF Advisers LLC cut its stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 10.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 483,000 shares of the company's stock after selling 56,989 shares during the quarter. Lifecore Biomedical accounts for 1.6% of DCF Advisers LLC's holdings, making the stock its 18th biggest position. DCF Advisers LLC owned 1.30% of Lifecore Biomedical worth $3,400,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in LFCR. Prudential Financial Inc. bought a new stake in shares of Lifecore Biomedical in the 4th quarter worth approximately $95,000. Geode Capital Management LLC lifted its position in shares of Lifecore Biomedical by 14.7% in the fourth quarter. Geode Capital Management LLC now owns 685,746 shares of the company's stock worth $5,097,000 after buying an additional 88,061 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Lifecore Biomedical by 29.0% in the fourth quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock worth $99,000 after buying an additional 3,012 shares during the period. Invesco Ltd. purchased a new stake in shares of Lifecore Biomedical during the 4th quarter valued at $4,128,000. Finally, Barclays PLC raised its stake in shares of Lifecore Biomedical by 13.5% during the 4th quarter. Barclays PLC now owns 33,972 shares of the company's stock valued at $253,000 after buying an additional 4,028 shares during the last quarter. Institutional investors own 83.36% of the company's stock.

Lifecore Biomedical Trading Down 1.9%

Lifecore Biomedical stock traded down $0.15 during midday trading on Thursday, hitting $7.58. 29,700 shares of the stock were exchanged, compared to its average volume of 222,980. The company has a quick ratio of 1.59, a current ratio of 2.71 and a debt-to-equity ratio of 66.36. The company has a fifty day simple moving average of $7.43 and a two-hundred day simple moving average of $6.70. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $8.85. The stock has a market capitalization of $280.69 million, a PE ratio of -5.21 and a beta of 0.65.

Wall Street Analysts Forecast Growth

Separately, William Blair initiated coverage on shares of Lifecore Biomedical in a research note on Wednesday, May 21st. They set an "outperform" rating for the company.

Insider Activity at Lifecore Biomedical

In other Lifecore Biomedical news, major shareholder Aron R. English sold 150,419 shares of the stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $7.12, for a total transaction of $1,070,983.28. Following the transaction, the insider directly owned 264,180 shares in the company, valued at $1,880,961.60. This trade represents a 36.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 1,444,792 shares of company stock worth $9,539,179. Insiders own 32.20% of the company's stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.